BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lord CJ, Ashworth A. Mechanisms of resistance to therapies targeting BRCA-mutant cancers. Nat Med 2013;19:1381-8. [PMID: 24202391 DOI: 10.1038/nm.3369] [Cited by in Crossref: 269] [Cited by in F6Publishing: 244] [Article Influence: 33.6] [Reference Citation Analysis]
Number Citing Articles
1 Aleksakhina SN, Kashyap A, Imyanitov EN. Mechanisms of acquired tumor drug resistance. Biochim Biophys Acta Rev Cancer. 2019;1872:188310. [PMID: 31442474 DOI: 10.1016/j.bbcan.2019.188310] [Cited by in Crossref: 39] [Cited by in F6Publishing: 42] [Article Influence: 19.5] [Reference Citation Analysis]
2 Dasa SSK, Diakova G, Suzuki R, Mills AM, Gutknecht MF, Klibanov AL, Slack-Davis JK, Kelly KA. Plectin-targeted liposomes enhance the therapeutic efficacy of a PARP inhibitor in the treatment of ovarian cancer. Theranostics 2018;8:2782-98. [PMID: 29774075 DOI: 10.7150/thno.23050] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 9.7] [Reference Citation Analysis]
3 Zemanek T, Melichar B, Lovecek M, Soucek P, Mohelnikova-Duchonova B. Biomarkers and pathways of chemoresistance and chemosensitivity for personalized treatment of pancreatic adenocarcinoma. Pharmacogenomics 2019;20:113-27. [PMID: 30539680 DOI: 10.2217/pgs-2018-0073] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
4 Iyevleva AG, Imyanitov EN. Cytotoxic and targeted therapy for hereditary cancers. Hered Cancer Clin Pract. 2016;14:17. [PMID: 27555886 DOI: 10.1186/s13053-016-0057-2] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 5.2] [Reference Citation Analysis]
5 Findlay JM, Castro-Giner F, Makino S, Rayner E, Kartsonaki C, Cross W, Kovac M, Ulahannan D, Palles C, Gillies RS, MacGregor TP, Church D, Maynard ND, Buffa F, Cazier JB, Graham TA, Wang LM, Sharma RA, Middleton M, Tomlinson I. Differential clonal evolution in oesophageal cancers in response to neo-adjuvant chemotherapy. Nat Commun 2016;7:11111. [PMID: 27045317 DOI: 10.1038/ncomms11111] [Cited by in Crossref: 52] [Cited by in F6Publishing: 51] [Article Influence: 10.4] [Reference Citation Analysis]
6 Wang YQ, Wang PY, Wang YT, Yang GF, Zhang A, Miao ZH. An Update on Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors: Opportunities and Challenges in Cancer Therapy. J Med Chem 2016;59:9575-98. [PMID: 27416328 DOI: 10.1021/acs.jmedchem.6b00055] [Cited by in Crossref: 95] [Cited by in F6Publishing: 87] [Article Influence: 19.0] [Reference Citation Analysis]
7 Mijic S, Zellweger R, Chappidi N, Berti M, Jacobs K, Mutreja K, Ursich S, Ray Chaudhuri A, Nussenzweig A, Janscak P, Lopes M. Replication fork reversal triggers fork degradation in BRCA2-defective cells. Nat Commun 2017;8:859. [PMID: 29038466 DOI: 10.1038/s41467-017-01164-5] [Cited by in Crossref: 172] [Cited by in F6Publishing: 144] [Article Influence: 43.0] [Reference Citation Analysis]
8 Frampton JE. Olaparib: a review of its use as maintenance therapy in patients with ovarian cancer. BioDrugs 2015;29:143-50. [PMID: 25899311 DOI: 10.1007/s40259-015-0125-6] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
9 Tangutoori S, Baldwin P, Sridhar S. PARP inhibitors: A new era of targeted therapy. Maturitas. 2015;81:5-9. [PMID: 25708226 DOI: 10.1016/j.maturitas.2015.01.015] [Cited by in Crossref: 79] [Cited by in F6Publishing: 77] [Article Influence: 13.2] [Reference Citation Analysis]
10 Zhang G, Liu C, Bai H, Cao G, Cui R, Zhang Z. Combinatorial therapy of immune checkpoint and cancer pathways provides a novel perspective on ovarian cancer treatment. Oncol Lett 2019;17:2583-91. [PMID: 30854033 DOI: 10.3892/ol.2019.9902] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
11 Desai D, Khandwala P, Parsi M, Potdar R. PARP inhibitors: shifting the paradigm in the treatment of pancreatic cancer. Med Oncol 2021;38:61. [PMID: 33891252 DOI: 10.1007/s12032-021-01507-9] [Reference Citation Analysis]
12 Zhao Y, Zhang L, Jiang T, Long J, Ma Z, Lu A, Cheng Y, Cao D. The ups and downs of Poly(ADP-ribose) Polymerase-1 inhibitors in cancer therapy–Current progress and future direction. European Journal of Medicinal Chemistry 2020;203:112570. [DOI: 10.1016/j.ejmech.2020.112570] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 14.0] [Reference Citation Analysis]
13 Dufour R, Daumar P, Mounetou E, Aubel C, Kwiatkowski F, Abrial C, Vatoux C, Penault-Llorca F, Bamdad M. BCRP and P-gp relay overexpression in triple negative basal-like breast cancer cell line: a prospective role in resistance to Olaparib. Sci Rep 2015;5:12670. [PMID: 26234720 DOI: 10.1038/srep12670] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
14 Rahmutulla B, Matsushita K, Nomura F. Alternative splicing of DNA damage response genes and gastrointestinal cancers. World J Gastroenterol 2014; 20(46): 17305-17313 [PMID: 25516641 DOI: 10.3748/wjg.v20.i46.17305] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
15 Toi M, Winer EP, Benson JR, Inamoto T, Forbes JF, von Minckwitz G, Robertson JF, Grobmyer SR, Jatoi I, Sasano H, Kunkler I, Ho AY, Yamauchi C, Chow LW, Huang C, Han W, Noguchi S, Pegram MD, Yamauchi H, Lee E, Larionov AA, Bevilacqua JL, Yoshimura M, Sugie T, Yamauchi A, Krop IE, Noh DY, Klimberg VS; 2014 Kyoto Breast Cancer Consensus Conference. Personalization of loco-regional care for primary breast cancer patients (part 2). Future Oncology 2015;11:1301-5. [DOI: 10.2217/fon.15.66] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
16 Ray Chaudhuri A, Nussenzweig A. Thwarting endogenous stress: BRCA protects against aldehyde toxicity. EMBO Mol Med 2017;9:1331-3. [PMID: 28835508 DOI: 10.15252/emmm.201708194] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
17 Wu S, Fatkhutdinov N, Fukumoto T, Bitler BG, Park PH, Kossenkov AV, Trizzino M, Tang HY, Zhang L, Gardini A, Speicher DW, Zhang R. SWI/SNF catalytic subunits' switch drives resistance to EZH2 inhibitors in ARID1A-mutated cells. Nat Commun 2018;9:4116. [PMID: 30297712 DOI: 10.1038/s41467-018-06656-6] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 6.7] [Reference Citation Analysis]
18 Kim Y, Kim A, Sharip A, Sharip A, Jiang J, Yang Q, Xie Y. Reverse the Resistance to PARP Inhibitors. Int J Biol Sci 2017;13:198-208. [PMID: 28255272 DOI: 10.7150/ijbs.17240] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 11.0] [Reference Citation Analysis]
19 Huang Z, Zhou L, Chen Z, Nice EC, Huang C. Stress management by autophagy: Implications for chemoresistance: Stress management by autophagy. Int J Cancer 2016;139:23-32. [DOI: 10.1002/ijc.29990] [Cited by in Crossref: 57] [Cited by in F6Publishing: 61] [Article Influence: 11.4] [Reference Citation Analysis]
20 Węsierska-Gądek J, Mauritz M, Mitulovic G, Cupo M. Differential Potential of Pharmacological PARP Inhibitors for Inhibiting Cell Proliferation and Inducing Apoptosis in Human Breast Cancer Cells. J Cell Biochem 2015;116:2824-39. [PMID: 25981734 DOI: 10.1002/jcb.25229] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
21 Goetze K, Fabian CG, Siebers A, Binz L, Faber D, Indraccolo S, Nardo G, Sattler UG, Mueller-Klieser W. Manipulation of tumor metabolism for therapeutic approaches: ovarian cancer-derived cell lines as a model system. Cell Oncol (Dordr) 2015;38:377-85. [PMID: 26288178 DOI: 10.1007/s13402-015-0237-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
22 Mateo J, Lord CJ, Serra V, Tutt A, Balmaña J, Castroviejo-Bermejo M, Cruz C, Oaknin A, Kaye SB, de Bono JS. A decade of clinical development of PARP inhibitors in perspective. Ann Oncol 2019;30:1437-47. [PMID: 31218365 DOI: 10.1093/annonc/mdz192] [Cited by in Crossref: 135] [Cited by in F6Publishing: 134] [Article Influence: 135.0] [Reference Citation Analysis]
23 Ma Y, He L, Huang Q, Zheng S, Zhang Z, Li H, Liu S. Response to olaparib in metastatic castration-resistant prostate cancer with germline BRCA2 mutation: a case report. BMC Med Genet 2018;19:185. [PMID: 30333000 DOI: 10.1186/s12881-018-0703-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
24 Kötter A, Cornils K, Borgmann K, Dahm-Daphi J, Petersen C, Dikomey E, Mansour WY. Inhibition of PARP1-dependent end-joining contributes to Olaparib-mediated radiosensitization in tumor cells. Mol Oncol 2014;8:1616-25. [PMID: 25028150 DOI: 10.1016/j.molonc.2014.06.008] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 4.7] [Reference Citation Analysis]
25 Adam J, Postel-Vinay S. Targeting cell cycle dependencies represent a novel therapeutic approach for selected sarcoma subgroups. Ann Oncol 2018;29:798-9. [PMID: 29528461 DOI: 10.1093/annonc/mdy088] [Reference Citation Analysis]
26 Węsierska-Gądek J, Heinzl S. Interactions Between Ataxia Telangiectasia Mutated Kinase Inhibition, Poly(ADP-ribose) Polymerase-1 Inhibition and BRCA1 Status in Breast Cancer Cells. J Cancer Prev 2014;19:125-36. [PMID: 25337581 DOI: 10.15430/JCP.2014.19.2.125] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
27 Demiray M. Combinatorial Therapy of High Dose Vitamin C and PARP Inhibitors in DNA Repair Deficiency: A Series of 8 Patients. Integr Cancer Ther 2020;19:1534735420969812. [PMID: 33150793 DOI: 10.1177/1534735420969812] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
28 Robert M, Patsouris A, Frenel J, Gourmelon C, Augereau P, Campone M. Emerging PARP inhibitors for treating breast cancer. Expert Opinion on Emerging Drugs 2018;23:211-21. [DOI: 10.1080/14728214.2018.1527900] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
29 Robert M, Frenel J, Gourmelon C, Patsouris A, Augereau P, Campone M. Olaparib for the treatment of breast cancer. Expert Opinion on Investigational Drugs 2017;26:751-9. [DOI: 10.1080/13543784.2017.1318847] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
30 Evans T, Matulonis U. PARP inhibitors in ovarian cancer: evidence, experience and clinical potential. Ther Adv Med Oncol 2017;9:253-67. [PMID: 28491146 DOI: 10.1177/1758834016687254] [Cited by in Crossref: 55] [Cited by in F6Publishing: 49] [Article Influence: 13.8] [Reference Citation Analysis]
31 Chiappa M, Guffanti F, Bertoni F, Colombo I, Damia G. Overcoming PARPi resistance: Preclinical and clinical evidence in ovarian cancer. Drug Resist Updat 2021;55:100744. [PMID: 33551306 DOI: 10.1016/j.drup.2021.100744] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
32 Eustermann S, Wu WF, Langelier MF, Yang JC, Easton LE, Riccio AA, Pascal JM, Neuhaus D. Structural Basis of Detection and Signaling of DNA Single-Strand Breaks by Human PARP-1. Mol Cell 2015;60:742-54. [PMID: 26626479 DOI: 10.1016/j.molcel.2015.10.032] [Cited by in Crossref: 139] [Cited by in F6Publishing: 131] [Article Influence: 23.2] [Reference Citation Analysis]
33 Couch FJ, Nathanson KL, Offit K. Two decades after BRCA: setting paradigms in personalized cancer care and prevention. Science 2014;343:1466-70. [PMID: 24675953 DOI: 10.1126/science.1251827] [Cited by in Crossref: 214] [Cited by in F6Publishing: 187] [Article Influence: 30.6] [Reference Citation Analysis]
34 Sokolenko AP, Savonevich EL, Ivantsov AO, Raskin GA, Kuligina ES, Gorodnova TV, Preobrazhenskaya EV, Kleshchov MA, Tiurin VI, Mukhina MS, Kotiv KB, Shulga AV, Kuznetsov SG, Berlev IV, Imyanitov EN. Rapid selection of BRCA1-proficient tumor cells during neoadjuvant therapy for ovarian cancer in BRCA1 mutation carriers. Cancer Lett. 2017;397:127-132. [PMID: 28377179 DOI: 10.1016/j.canlet.2017.03.036] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
35 Isobe SY, Hiraga SI, Nagao K, Sasanuma H, Donaldson AD, Obuse C. Protein phosphatase 1 acts as a RIF1 effector to suppress DSB resection prior to Shieldin action. Cell Rep 2021;36:109383. [PMID: 34260925 DOI: 10.1016/j.celrep.2021.109383] [Reference Citation Analysis]
36 Luo S, Zhang Y, Yang Y, Zhu S, Liu W, Zhu J, Liang X, Jiang Z, Sun S, Hou X, Xiao Y, Li X. Clonal tumor mutations in homologous recombination genes predict favorable clinical outcome in ovarian cancer treated with platinum-based chemotherapy. Gynecol Oncol 2020;158:66-76. [PMID: 32402633 DOI: 10.1016/j.ygyno.2020.04.695] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
37 Baliu-Piqué M, Pandiella A, Ocana A. Breast Cancer Heterogeneity and Response to Novel Therapeutics. Cancers (Basel) 2020;12:E3271. [PMID: 33167363 DOI: 10.3390/cancers12113271] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
38 Murai J, Feng Y, Yu GK, Ru Y, Tang SW, Shen Y, Pommier Y. Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition. Oncotarget 2016;7:76534-50. [PMID: 27708213 DOI: 10.18632/oncotarget.12266] [Cited by in Crossref: 122] [Cited by in F6Publishing: 114] [Article Influence: 40.7] [Reference Citation Analysis]
39 Hu HM, Zhao X, Kaushik S, Robillard L, Barthelet A, Lin KK, Shah KN, Simmons AD, Raponi M, Harding TC, Bandyopadhyay S. A Quantitative Chemotherapy Genetic Interaction Map Reveals Factors Associated with PARP Inhibitor Resistance. Cell Rep 2018;23:918-29. [PMID: 29669295 DOI: 10.1016/j.celrep.2018.03.093] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 10.0] [Reference Citation Analysis]
40 Ozden O, Bishehsari F, Bauer J, Park SH, Jana A, Baik SH, Sporn JC, Staudacher JJ, Yazici C, Krett N, Jung B. Expression of an Oncogenic BARD1 Splice Variant Impairs Homologous Recombination and Predicts Response to PARP-1 Inhibitor Therapy in Colon Cancer. Sci Rep 2016;6:26273. [PMID: 27197561 DOI: 10.1038/srep26273] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
41 Hsu PC, Gopinath RK, Hsueh YA, Shieh SY. CHK2-mediated regulation of PARP1 in oxidative DNA damage response. Oncogene 2019;38:1166-82. [PMID: 30254210 DOI: 10.1038/s41388-018-0506-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
42 Conlon JM, Attoub S, Musale V, Leprince J, Casewell NR, Sanz L, Calvete JJ. Isolation and characterization of cytotoxic and insulin-releasing components from the venom of the black-necked spitting cobra Naja nigricollis (Elapidae). Toxicon X 2020;6:100030. [PMID: 32550585 DOI: 10.1016/j.toxcx.2020.100030] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
43 Bakr A, Köcher S, Volquardsen J, Petersen C, Borgmann K, Dikomey E, Rothkamm K, Mansour WY. Impaired 53BP1/RIF1 DSB mediated end-protection stimulates CtIP-dependent end resection and switches the repair to PARP1-dependent end joining in G1. Oncotarget 2016;7:57679-93. [PMID: 27494840 DOI: 10.18632/oncotarget.11023] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
44 Zhang G, Yang JY, Cui Z. New insight into cancer aneuploidy in zebrafish. Int Rev Cell Mol Biol 2015;314:149-70. [PMID: 25619717 DOI: 10.1016/bs.ircmb.2014.09.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
45 Hurley RM, Wahner Hendrickson AE, Visscher DW, Ansell P, Harrell MI, Wagner JM, Negron V, Goergen KM, Maurer MJ, Oberg AL, Meng XW, Flatten KS, De Jonge MJA, Van Herpen CD, Gietema JA, Koornstra RHT, Jager A, den Hollander MW, Dudley M, Shepherd SP, Swisher EM, Kaufmann SH. 53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer. Gynecol Oncol. 2019;153:127-134. [PMID: 30686551 DOI: 10.1016/j.ygyno.2019.01.015] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 13.0] [Reference Citation Analysis]
46 Gong L, Cui D, Xiong X, Zhao Y. Targeting Cullin-RING Ubiquitin Ligases and the Applications in PROTACs. In: Sun Y, Wei W, Jin J, editors. Cullin-RING Ligases and Protein Neddylation. Singapore: Springer; 2020. pp. 317-47. [DOI: 10.1007/978-981-15-1025-0_19] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
47 Awate S, Sommers JA, Datta A, Nayak S, Bellani MA, Yang O, Dunn CA, Nicolae CM, Moldovan GL, Seidman MM, Cantor SB, Brosh RM. FANCJ compensates for RAP80 deficiency and suppresses genomic instability induced by interstrand cross-links. Nucleic Acids Res 2020;48:9161-80. [PMID: 32797166 DOI: 10.1093/nar/gkaa660] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
48 Guney Eskiler G, Cecener G, Egeli U, Tunca B. Talazoparib nanoparticles for overcoming multidrug resistance in triple-negative breast cancer. J Cell Physiol 2020;235:6230-45. [PMID: 32017076 DOI: 10.1002/jcp.29552] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
49 Nieborowska-Skorska M, Maifrede S, Ye M, Toma M, Hewlett E, Gordon J, Le BV, Sliwinski T, Zhao H, Piwocka K, Valent P, Tulin AV, Childers W, Skorski T. Non-NAD-like PARP1 inhibitor enhanced synthetic lethal effect of NAD-like PARP inhibitors against BRCA1-deficient leukemia. Leuk Lymphoma 2019;60:1098-101. [PMID: 30277116 DOI: 10.1080/10428194.2018.1520988] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
50 Hurley RM, McGehee CD, Nesic K, Correia C, Weiskittel TM, Kelly RL, Venkatachalam A, Hou X, Pathoulas NM, Meng XW, Kondrashova O, Radke MR, Schneider PA, Flatten KS, Peterson KL, Becker MA, Wong EM, Southey MS, Dobrovic A, Lin KK, Harding TC, McNeish I, Ross CA, Wagner JM, Wakefield MJ, Scott CL, Haluska P, Wahner Hendrickson AE, Karnitz LM, Swisher EM, Li H, Weroha SJ, Kaufmann SH. Characterization of a RAD51C-silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistance. NAR Cancer 2021;3:zcab028. [PMID: 34316715 DOI: 10.1093/narcan/zcab028] [Reference Citation Analysis]
51 White ER, Sun L, Ma Z, Beckta JM, Danzig BA, Hacker DE, Huie M, Williams DC, Edwards RA, Valerie K, Glover JN, Hartman MC. Peptide library approach to uncover phosphomimetic inhibitors of the BRCA1 C-terminal domain. ACS Chem Biol 2015;10:1198-208. [PMID: 25654734 DOI: 10.1021/cb500757u] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
52 Kim JY, Cho CH, Song HS. Targeted therapy of ovarian cancer including immune check point inhibitor. Korean J Intern Med 2017;32:798-804. [PMID: 28823141 DOI: 10.3904/kjim.2017.008] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 5.5] [Reference Citation Analysis]
53 Pillay N, Brady RM, Dey M, Morgan RD, Taylor SS. DNA replication stress and emerging prospects for PARG inhibitors in ovarian cancer therapy. Prog Biophys Mol Biol 2021;163:160-70. [PMID: 33524442 DOI: 10.1016/j.pbiomolbio.2021.01.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
54 Krukenberg KA, Jiang R, Steen JA, Mitchison TJ. Basal activity of a PARP1-NuA4 complex varies dramatically across cancer cell lines. Cell Rep 2014;8:1808-18. [PMID: 25199834 DOI: 10.1016/j.celrep.2014.08.009] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
55 Han J, Huang J. DNA double-strand break repair pathway choice: the fork in the road. GENOME INSTAB DIS 2020;1:10-9. [DOI: 10.1007/s42764-019-00002-w] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
56 Coleman RL, Sill MW, Bell-McGuinn K, Aghajanian C, Gray HJ, Tewari KS, Rubin SC, Rutherford TJ, Chan JK, Chen A, Swisher EM. A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol 2015;137:386-91. [PMID: 25818403 DOI: 10.1016/j.ygyno.2015.03.042] [Cited by in Crossref: 155] [Cited by in F6Publishing: 149] [Article Influence: 25.8] [Reference Citation Analysis]
57 Ratajczak MZ, Jadczyk T, Schneider G, Kakar SS, Kucia M. Induction of a tumor-metastasis-receptive microenvironment as an unwanted and underestimated side effect of treatment by chemotherapy or radiotherapy. J Ovarian Res 2013;6:95. [PMID: 24373588 DOI: 10.1186/1757-2215-6-95] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 4.4] [Reference Citation Analysis]
58 Lheureux S, Oza AM. Olaparib for the treatment of ovarian cancer. Expert Opinion on Orphan Drugs 2014;2:497-508. [DOI: 10.1517/21678707.2014.899147] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
59 Cooley M, Fang P, Fang F, Nephew KP, Chien J. Molecular determinants of chemotherapy resistance in ovarian cancer. Pharmacogenomics 2015;16:1763-7. [PMID: 26554863 DOI: 10.2217/pgs.15.130] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
60 Stewart J, George A, Banerjee S. Olaparib for the treatment of relapsed ovarian cancer with a BRCA1/2 mutation. Expert Review of Anticancer Therapy 2018;18:947-58. [DOI: 10.1080/14737140.2018.1510323] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
61 Pilzecker B, Buoninfante OA, Jacobs H. DNA damage tolerance in stem cells, ageing, mutagenesis, disease and cancer therapy. Nucleic Acids Res 2019;47:7163-81. [PMID: 31251805 DOI: 10.1093/nar/gkz531] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 11.0] [Reference Citation Analysis]
62 Volpe J, Filipi JG, Cooper OR, Penson RT. Frontline therapy of ovarian cancer: trials and tribulations. Current Opinion in Obstetrics & Gynecology 2018;30:1-6. [DOI: 10.1097/gco.0000000000000434] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
63 Carrassa L, Colombo I, Damia G, Bertoni F. Targeting the DNA damage response for patients with lymphoma: Preclinical and clinical evidences. Cancer Treatment Reviews 2020;90:102090. [DOI: 10.1016/j.ctrv.2020.102090] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
64 Sokolenko AP, Imyanitov EN. Molecular Diagnostics in Clinical Oncology. Front Mol Biosci 2018;5:76. [PMID: 30211169 DOI: 10.3389/fmolb.2018.00076] [Cited by in Crossref: 40] [Cited by in F6Publishing: 33] [Article Influence: 13.3] [Reference Citation Analysis]
65 Hayward SB, Ciccia A. Towards a CRISPeR understanding of homologous recombination with high-throughput functional genomics. Curr Opin Genet Dev 2021;71:171-81. [PMID: 34583241 DOI: 10.1016/j.gde.2021.08.006] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
66 Jimenez-Sainz J, Jensen RB. Imprecise Medicine: BRCA2 Variants of Uncertain Significance (VUS), the Challenges and Benefits to Integrate a Functional Assay Workflow with Clinical Decision Rules. Genes (Basel) 2021;12:780. [PMID: 34065235 DOI: 10.3390/genes12050780] [Reference Citation Analysis]
67 Lokadasan R, James FV, Narayanan G, Prabhakaran PK. Targeted agents in epithelial ovarian cancer: review on emerging therapies and future developments. Ecancermedicalscience 2016;10:626. [PMID: 27110282 DOI: 10.3332/ecancer.2016.626] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
68 Walsh MF, Nathanson KL, Couch FJ, Offit K. Genomic Biomarkers for Breast Cancer Risk. Adv Exp Med Biol 2016;882:1-32. [PMID: 26987529 DOI: 10.1007/978-3-319-22909-6_1] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 4.6] [Reference Citation Analysis]
69 Villalona-Calero MA, Duan W, Zhao W, Shilo K, Schaaf LJ, Thurmond J, Westman JA, Marshall J, Xiaobai L, Ji J, Rose J, Lustberg M, Bekaii-Saab T, Chen A, Timmers C. Veliparib Alone or in Combination with Mitomycin C in Patients with Solid Tumors With Functional Deficiency in Homologous Recombination Repair. J Natl Cancer Inst 2016;108. [PMID: 26848151 DOI: 10.1093/jnci/djv437] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
70 Geenen JJJ, Linn SC, Beijnen JH, Schellens JHM. PARP Inhibitors in the Treatment of Triple-Negative Breast Cancer. Clin Pharmacokinet 2018;57:427-37. [PMID: 29063517 DOI: 10.1007/s40262-017-0587-4] [Cited by in Crossref: 37] [Cited by in F6Publishing: 30] [Article Influence: 18.5] [Reference Citation Analysis]
71 Wei L, Leibowitz BJ, Wang X, Epperly M, Greenberger J, Zhang L, Yu J. Inhibition of CDK4/6 protects against radiation-induced intestinal injury in mice. J Clin Invest 2016;126:4076-87. [PMID: 27701148 DOI: 10.1172/JCI88410] [Cited by in Crossref: 43] [Cited by in F6Publishing: 27] [Article Influence: 8.6] [Reference Citation Analysis]
72 Choo SM, Ban B, Joo JI, Cho KH. The phenotype control kernel of a biomolecular regulatory network. BMC Syst Biol 2018;12:49. [PMID: 29622038 DOI: 10.1186/s12918-018-0576-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
73 Wu Y, Zhong D, Li Y, Wu H, Xu X, Yang J, Gu Z. Tumor-Oriented Telomerase-Terminated Nanoplatform as Versatile Strategy for Multidrug Resistance Reversal in Cancer Treatment. Adv Healthc Mater 2020;9:e1901739. [PMID: 32125789 DOI: 10.1002/adhm.201901739] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
74 Guo T, Chen T, Gu C, Li B, Xu C. Genetic and molecular analyses reveal G6PC as a key element connecting glucose metabolism and cell cycle control in ovarian cancer. Tumour Biol 2015;36:7649-58. [PMID: 25926381 DOI: 10.1007/s13277-015-3463-6] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.7] [Reference Citation Analysis]
75 de Bitter T, van de Water C, van den Heuvel C, Zeelen C, Eijkelenboom A, Tops B, Oosterwijk E, Kolev D, Mulders P, Ter Laan M, van Lith S, Leenders W. Profiling of the metabolic transcriptome via single molecule molecular inversion probes. Sci Rep 2017;7:11402. [PMID: 28900252 DOI: 10.1038/s41598-017-11035-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
76 Patterson-Fortin J, D'Andrea AD. Exploiting the Microhomology-Mediated End-Joining Pathway in Cancer Therapy. Cancer Res 2020;80:4593-600. [PMID: 32651257 DOI: 10.1158/0008-5472.CAN-20-1672] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 10.0] [Reference Citation Analysis]
77 Zhu H, Wei M, Xu J, Hua J, Liang C, Meng Q, Zhang Y, Liu J, Zhang B, Yu X, Shi S. PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications. Mol Cancer 2020;19:49. [PMID: 32122376 DOI: 10.1186/s12943-020-01167-9] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 40.0] [Reference Citation Analysis]
78 Santarpia L, Bottai G, Kelly CM, Győrffy B, Székely B, Pusztai L. Deciphering and Targeting Oncogenic Mutations and Pathways in Breast Cancer. Oncologist 2016;21:1063-78. [PMID: 27384237 DOI: 10.1634/theoncologist.2015-0369] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 6.0] [Reference Citation Analysis]
79 Gorodnova TV, Kotiv KB, Ivantsov AO, Mikheyeva ON, Mikhailiuk GI, Lisyanskaya AS, Mikaya NA, Guseynov KD, Bondarev NE, Matveyeva NS, Nekrasova EA, Sidoruk AA, Roman LD, Manikhas GM, Belyaev AM, Sokolenko AP, Berlev IV, Imyanitov EN. Efficacy of Neoadjuvant Therapy With Cisplatin Plus Mitomycin C in BRCA1-Mutated Ovarian Cancer. Int J Gynecol Cancer 2018;28:1498-506. [PMID: 30247247 DOI: 10.1097/IGC.0000000000001352] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 4.5] [Reference Citation Analysis]
80 Wang Y, Bernhardy AJ, Cruz C, Krais JJ, Nacson J, Nicolas E, Peri S, van der Gulden H, van der Heijden I, O'Brien SW, Zhang Y, Harrell MI, Johnson SF, Candido Dos Reis FJ, Pharoah PD, Karlan B, Gourley C, Lambrechts D, Chenevix-Trench G, Olsson H, Benitez JJ, Greene MH, Gore M, Nussbaum R, Sadetzki S, Gayther SA, Kjaer SK, D'Andrea AD, Shapiro GI, Wiest DL, Connolly DC, Daly MB, Swisher EM, Bouwman P, Jonkers J, Balmaña J, Serra V, Johnson N; kConFab Investigators. The BRCA1-Δ11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin. Cancer Res 2016;76:2778-90. [PMID: 27197267 DOI: 10.1158/0008-5472.CAN-16-0186] [Cited by in Crossref: 108] [Cited by in F6Publishing: 66] [Article Influence: 27.0] [Reference Citation Analysis]
81 Drané P, Brault ME, Cui G, Meghani K, Chaubey S, Detappe A, Parnandi N, He Y, Zheng XF, Botuyan MV, Kalousi A, Yewdell WT, Münch C, Harper JW, Chaudhuri J, Soutoglou E, Mer G, Chowdhury D. TIRR regulates 53BP1 by masking its histone methyl-lysine binding function. Nature 2017;543:211-6. [PMID: 28241136 DOI: 10.1038/nature21358] [Cited by in Crossref: 61] [Cited by in F6Publishing: 55] [Article Influence: 15.3] [Reference Citation Analysis]
82 Kais Z, Rondinelli B, Holmes A, O'Leary C, Kozono D, D'Andrea AD, Ceccaldi R. FANCD2 Maintains Fork Stability in BRCA1/2-Deficient Tumors and Promotes Alternative End-Joining DNA Repair. Cell Rep 2016;15:2488-99. [PMID: 27264184 DOI: 10.1016/j.celrep.2016.05.031] [Cited by in Crossref: 86] [Cited by in F6Publishing: 81] [Article Influence: 17.2] [Reference Citation Analysis]
83 Reilly NM, Yard BD, Pittman DL. Homologous Recombination-Mediated DNA Repair and Implications for Clinical Treatment of Repair Defective Cancers. Methods Mol Biol 2019;1999:3-29. [PMID: 31127567 DOI: 10.1007/978-1-4939-9500-4_1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
84 Yuan Z, Chen J, Li W, Li D, Chen C, Gao C, Jiang Y. PARP inhibitors as antitumor agents: a patent update (2013-2015). Expert Opin Ther Pat 2017;27:363-82. [PMID: 27841036 DOI: 10.1080/13543776.2017.1259413] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
85 Gou R, Dong H, Lin B. Application and reflection of genomic scar assays in evaluating the efficacy of platinum salts and PARP inhibitors in cancer therapy. Life Sci 2020;261:118434. [PMID: 32941897 DOI: 10.1016/j.lfs.2020.118434] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
86 Wéra AC, Lobbens A, Stoyanov M, Lucas S, Michiels C. Radiation-induced synthetic lethality: combination of poly(ADP-ribose) polymerase and RAD51 inhibitors to sensitize cells to proton irradiation. Cell Cycle 2019;18:1770-83. [PMID: 31238782 DOI: 10.1080/15384101.2019.1632640] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
87 Chen X, Peng F, Ji Y, Xiang H, Wang X, Liu T, Wang H, Han Y, Wang C, Zhang Y, Kong X, Lang JY. Brca2 deficiency drives gastrointestinal tumor formation and is selectively inhibited by mitomycin C. Cell Death Dis 2020;11:812. [PMID: 32980867 DOI: 10.1038/s41419-020-03013-8] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
88 Li M, Yu X. The role of poly(ADP-ribosyl)ation in DNA damage response and cancer chemotherapy. Oncogene 2015;34:3349-56. [PMID: 25220415 DOI: 10.1038/onc.2014.295] [Cited by in Crossref: 66] [Cited by in F6Publishing: 66] [Article Influence: 9.4] [Reference Citation Analysis]
89 Golan T, Stossel C, Atias D, Buzhor E, Halperin S, Cohen K, Raitses-Gurevich M, Glick Y, Raskin S, Yehuda D, Feldman A, Schvimer M, Friedman E, Karni R, Wilson JM, Denroche RE, Lungu I, Bartlett JMS, Mbabaali F, Gallinger S, Berger R. Recapitulating the clinical scenario of BRCA-associated pancreatic cancer in pre-clinical models. Int J Cancer 2018;143:179-83. [PMID: 29396858 DOI: 10.1002/ijc.31292] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
90 Weigelt B, Comino-Méndez I, de Bruijn I, Tian L, Meisel JL, García-Murillas I, Fribbens C, Cutts R, Martelotto LG, Ng CKY, Lim RS, Selenica P, Piscuoglio S, Aghajanian C, Norton L, Murali R, Hyman DM, Borsu L, Arcila ME, Konner J, Reis-Filho JS, Greenberg RA, Robson ME, Turner NC. Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer. Clin Cancer Res 2017;23:6708-20. [PMID: 28765325 DOI: 10.1158/1078-0432.CCR-17-0544] [Cited by in Crossref: 112] [Cited by in F6Publishing: 47] [Article Influence: 28.0] [Reference Citation Analysis]
91 Liu FW, Tewari KS. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors. Curr Treat Options Oncol 2016;17:12. [PMID: 26931795 DOI: 10.1007/s11864-015-0378-9] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 4.6] [Reference Citation Analysis]
92 Yang H, Jaeger M, Walker A, Wei D, Leiker K, Weitao T. Break Breast Cancer Addiction by CRISPR/Cas9 Genome Editing. J Cancer 2018;9:219-31. [PMID: 29344267 DOI: 10.7150/jca.22554] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
93 Yazinski SA, Comaills V, Buisson R, Genois MM, Nguyen HD, Ho CK, Todorova Kwan T, Morris R, Lauffer S, Nussenzweig A, Ramaswamy S, Benes CH, Haber DA, Maheswaran S, Birrer MJ, Zou L. ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells. Genes Dev 2017;31:318-32. [PMID: 28242626 DOI: 10.1101/gad.290957.116] [Cited by in Crossref: 167] [Cited by in F6Publishing: 151] [Article Influence: 41.8] [Reference Citation Analysis]
94 Park PH, Yamamoto TM, Li H, Alcivar AL, Xia B, Wang Y, Bernhardy AJ, Turner KM, Kossenkov AV, Watson ZL, Behbakht K, Casadei S, Swisher EM, Mischel PS, Johnson N, Bitler BG. Amplification of the Mutation-Carrying BRCA2 Allele Promotes RAD51 Loading and PARP Inhibitor Resistance in the Absence of Reversion Mutations. Mol Cancer Ther. 2020;19:602-613. [PMID: 31575654 DOI: 10.1158/1535-7163.mct-17-0256] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
95 Sachdev E, Tabatabai R, Roy V, Rimel BJ, Mita MM. PARP Inhibition in Cancer: An Update on Clinical Development. Target Oncol 2019;14:657-79. [PMID: 31625002 DOI: 10.1007/s11523-019-00680-2] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 37.0] [Reference Citation Analysis]
96 Mei L, Zhang J, He K, Zhang J. Ataxia telangiectasia and Rad3-related inhibitors and cancer therapy: where we stand. J Hematol Oncol 2019;12:43. [PMID: 31018854 DOI: 10.1186/s13045-019-0733-6] [Cited by in Crossref: 55] [Cited by in F6Publishing: 43] [Article Influence: 27.5] [Reference Citation Analysis]
97 Lord CJ, Ashworth A. BRCAness revisited. Nat Rev Cancer 2016;16:110-20. [PMID: 26775620 DOI: 10.1038/nrc.2015.21] [Cited by in Crossref: 576] [Cited by in F6Publishing: 517] [Article Influence: 115.2] [Reference Citation Analysis]
98 Zhu Q, Han SX, Zhou CY, Cai MJ, Dai LP, Zhang JY. Autoimmune response to PARP and BRCA1/BRCA2 in cancer. Oncotarget 2015;6:11575-84. [PMID: 25865228 DOI: 10.18632/oncotarget.3428] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.6] [Reference Citation Analysis]
99 Nikolaev A, Yang ES. The Impact of DNA Repair Pathways in Cancer Biology and Therapy. Cancers (Basel) 2017;9:E126. [PMID: 28925933 DOI: 10.3390/cancers9090126] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
100 Buechel M, Herzog TJ, Westin SN, Coleman RL, Monk BJ, Moore KN. Treatment of patients with recurrent epithelial ovarian cancer for whom platinum is still an option. Ann Oncol 2019;30:721-32. [PMID: 30887020 DOI: 10.1093/annonc/mdz104] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 15.0] [Reference Citation Analysis]
101 Bast RC Jr, Matulonis UA, Sood AK, Ahmed AA, Amobi AE, Balkwill FR, Wielgos-Bonvallet M, Bowtell DDL, Brenton JD, Brugge JS, Coleman RL, Draetta GF, Doberstein K, Drapkin RI, Eckert MA, Edwards RP, Elias KM, Ennis D, Futreal A, Gershenson DM, Greenberg RA, Huntsman DG, Ji JXY, Kohn EC, Iavarone C, Lengyel ER, Levine DA, Lord CJ, Lu Z, Mills GB, Modugno F, Nelson BH, Odunsi K, Pilsworth JA, Rottapel RK, Powell DJ Jr, Shen L, Shih IM, Spriggs DR, Walton J, Zhang K, Zhang R, Zou L. Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference. Cancer 2019;125:1963-72. [PMID: 30835824 DOI: 10.1002/cncr.32004] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 9.5] [Reference Citation Analysis]
102 Banerjee SN, Lord CJ. First-line PARP inhibition in ovarian cancer - standard of care for all? Nat Rev Clin Oncol 2020;17:136-7. [PMID: 32051558 DOI: 10.1038/s41571-020-0335-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 12.0] [Reference Citation Analysis]
103 Windisch R, Pirschtat N, Kellner C, Chen-Wichmann L, Lausen J, Humpe A, Krause DS, Wichmann C. Oncogenic Deregulation of Cell Adhesion Molecules in Leukemia. Cancers (Basel) 2019;11:E311. [PMID: 30841639 DOI: 10.3390/cancers11030311] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
104 Jain CK, Mukhopadhyay S, Ganguly A. RecQ Family Helicases in Replication Fork Remodeling and Repair: Opening New Avenues towards the Identification of Potential Targets for Cancer Chemotherapy. Anticancer Agents Med Chem 2020;20:1311-26. [PMID: 32418530 DOI: 10.2174/1871520620666200518082433] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
105 Paviolo NS, Vega MB, Pansa MF, García IA, Calzetta NL, Soria G, Gottifredi V. Persistent double strand break accumulation does not precede cell death in an Olaparib-sensitive BRCA-deficient colorectal cancer cell model. Genet Mol Biol 2019;43:e20190070. [PMID: 31930278 DOI: 10.1590/1678-4685-GMB-2019-0070] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
106 Rondinelli B, Gogola E, Yücel H, Duarte AA, van de Ven M, van der Sluijs R, Konstantinopoulos PA, Jonkers J, Ceccaldi R, Rottenberg S, D'Andrea AD. EZH2 promotes degradation of stalled replication forks by recruiting MUS81 through histone H3 trimethylation. Nat Cell Biol 2017;19:1371-8. [PMID: 29035360 DOI: 10.1038/ncb3626] [Cited by in Crossref: 143] [Cited by in F6Publishing: 136] [Article Influence: 35.8] [Reference Citation Analysis]
107 Li X, Wu Z, An X, Mei Q, Bai M, Hanski L, Li X, Ahola T, Han W. Blockade of the LRP16-PKR-NF-κB signaling axis sensitizes colorectal carcinoma cells to DNA-damaging cytotoxic therapy. Elife 2017;6:e27301. [PMID: 28820388 DOI: 10.7554/eLife.27301] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.8] [Reference Citation Analysis]
108 Ray Chaudhuri A, Callen E, Ding X, Gogola E, Duarte AA, Lee JE, Wong N, Lafarga V, Calvo JA, Panzarino NJ, John S, Day A, Crespo AV, Shen B, Starnes LM, de Ruiter JR, Daniel JA, Konstantinopoulos PA, Cortez D, Cantor SB, Fernandez-Capetillo O, Ge K, Jonkers J, Rottenberg S, Sharan SK, Nussenzweig A. Replication fork stability confers chemoresistance in BRCA-deficient cells. Nature. 2016;535:382-387. [PMID: 27443740 DOI: 10.1038/nature18325] [Cited by in Crossref: 395] [Cited by in F6Publishing: 356] [Article Influence: 79.0] [Reference Citation Analysis]
109 Dror CM, Wyatt AW, Chi KN. Olaparib for the treatment of metastatic prostate cancer. Future Oncol 2021;17:2413-29. [PMID: 33769071 DOI: 10.2217/fon-2020-1245] [Reference Citation Analysis]
110 Rytelewski M, Maleki Vareki S, Mangala LS, Romanow L, Jiang D, Pradeep S, Rodriguez-Aguayo C, Lopez-Berestein G, Figueredo R, Ferguson PJ, Vincent M, Sood AK, Koropatnick JD. Reciprocal positive selection for weakness - preventing olaparib resistance by inhibiting BRCA2. Oncotarget 2016;7:20825-39. [PMID: 26959114 DOI: 10.18632/oncotarget.7883] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
111 Houghton PJ, Kurmasheva RT. Challenges and Opportunities for Childhood Cancer Drug Development. Pharmacol Rev 2019;71:671-97. [PMID: 31558580 DOI: 10.1124/pr.118.016972] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
112 Xu G, Chapman JR, Brandsma I, Yuan J, Mistrik M, Bouwman P, Bartkova J, Gogola E, Warmerdam D, Barazas M, Jaspers JE, Watanabe K, Pieterse M, Kersbergen A, Sol W, Celie PHN, Schouten PC, van den Broek B, Salman A, Nieuwland M, de Rink I, de Ronde J, Jalink K, Boulton SJ, Chen J, van Gent DC, Bartek J, Jonkers J, Borst P, Rottenberg S. REV7 counteracts DNA double-strand break resection and affects PARP inhibition. Nature 2015;521:541-4. [PMID: 25799992 DOI: 10.1038/nature14328] [Cited by in Crossref: 335] [Cited by in F6Publishing: 302] [Article Influence: 55.8] [Reference Citation Analysis]
113 Wang G, Zhao D, Spring DJ, DePinho RA. Genetics and biology of prostate cancer. Genes Dev 2018;32:1105-40. [PMID: 30181359 DOI: 10.1101/gad.315739.118] [Cited by in Crossref: 110] [Cited by in F6Publishing: 101] [Article Influence: 36.7] [Reference Citation Analysis]
114 Segovia R, Shen Y, Lujan SA, Jones SJ, Stirling PC. Hypermutation signature reveals a slippage and realignment model of translesion synthesis by Rev3 polymerase in cisplatin-treated yeast. Proc Natl Acad Sci U S A 2017;114:2663-8. [PMID: 28223526 DOI: 10.1073/pnas.1618555114] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
115 Engert F, Kovac M, Baumhoer D, Nathrath M, Fulda S. Osteosarcoma cells with genetic signatures of BRCAness are susceptible to the PARP inhibitor talazoparib alone or in combination with chemotherapeutics. Oncotarget 2017;8:48794-806. [PMID: 27447864 DOI: 10.18632/oncotarget.10720] [Cited by in Crossref: 47] [Cited by in F6Publishing: 46] [Article Influence: 15.7] [Reference Citation Analysis]
116 Conlon JM, Mechkarska M, Lukic ML, Flatt PR. Potential therapeutic applications of multifunctional host-defense peptides from frog skin as anti-cancer, anti-viral, immunomodulatory, and anti-diabetic agents. Peptides 2014;57:67-77. [PMID: 24793775 DOI: 10.1016/j.peptides.2014.04.019] [Cited by in Crossref: 111] [Cited by in F6Publishing: 101] [Article Influence: 15.9] [Reference Citation Analysis]
117 Hossain MZ, Patel K, Kern SE. Salivary α-amylase, serum albumin, and myoglobin protect against DNA-damaging activities of ingested dietary agents in vitro. Food Chem Toxicol 2014;70:114-9. [PMID: 24842839 DOI: 10.1016/j.fct.2014.05.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
118 Rajawat J, Shukla N, Mishra DP. Therapeutic Targeting of Poly(ADP-Ribose) Polymerase-1 (PARP1) in Cancer: Current Developments, Therapeutic Strategies, and Future Opportunities. Med Res Rev 2017;37:1461-91. [PMID: 28510338 DOI: 10.1002/med.21442] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 7.8] [Reference Citation Analysis]
119 Ali SM, Watson J, Wang K, Chung JH, McMahon C, Ross JS, Dicke KA. A Combination of Targeted Therapy with Chemotherapy Backbone Induces Response in a Treatment-Resistant Triple-Negative MCL1-Amplified Metastatic Breast Cancer Patient. Case Rep Oncol 2016;9:112-8. [PMID: 27293397 DOI: 10.1159/000443371] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
120 Daumar P, Dufour R, Dubois C, Penault-llorca F, Bamdad M, Mounetou E. Development and validation of a high-performance liquid chromatography method for the quantitation of intracellular PARP inhibitor Olaparib in cancer cells. Journal of Pharmaceutical and Biomedical Analysis 2018;152:74-80. [DOI: 10.1016/j.jpba.2018.01.036] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
121 Liu JF, Konstantinopoulos PA, Matulonis UA. PARP inhibitors in ovarian cancer: Current status and future promise. Gynecologic Oncology 2014;133:362-9. [DOI: 10.1016/j.ygyno.2014.02.039] [Cited by in Crossref: 93] [Cited by in F6Publishing: 85] [Article Influence: 13.3] [Reference Citation Analysis]
122 Hong R, Ma F, Zhang W, Yu X, Li Q, Luo Y, Zhu C, Jiang W, Xu B. 53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells. BMC Cancer 2016;16:725. [PMID: 27613518 DOI: 10.1186/s12885-016-2754-7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
123 Bååth M, Jönsson JM, Westbom Fremer S, Martín de la Fuente L, Tran L, Malander S, Kannisto P, Måsbäck A, Honeth G, Hedenfalk I. MET Expression and Cancer Stem Cell Networks Impact Outcome in High-Grade Serous Ovarian Cancer. Genes (Basel) 2021;12:742. [PMID: 34069138 DOI: 10.3390/genes12050742] [Reference Citation Analysis]
124 La Ferla M, Mercatanti A, Rocchi G, Lodovichi S, Cervelli T, Pignata L, Caligo MA, Galli A. Expression of human poly (ADP-ribose) polymerase 1 in Saccharomyces cerevisiae: Effect on survival, homologous recombination and identification of genes involved in intracellular localization. Mutat Res 2015;774:14-24. [PMID: 25779917 DOI: 10.1016/j.mrfmmm.2015.02.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
125 Alemasova EE, Naumenko KN, Kurgina TA, Anarbaev RO, Lavrik OI. The multifunctional protein YB-1 potentiates PARP1 activity and decreases the efficiency of PARP1 inhibitors. Oncotarget 2018;9:23349-65. [PMID: 29805738 DOI: 10.18632/oncotarget.25158] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
126 Lorusso D, Tripodi E, Maltese G, Lepori S, Sabatucci I, Bogani G, Raspagliesi F. Spotlight on olaparib in the treatment of BRCA-mutated ovarian cancer: design, development and place in therapy. Drug Des Devel Ther 2018;12:1501-9. [PMID: 29881257 DOI: 10.2147/DDDT.S124447] [Cited by in Crossref: 22] [Cited by in F6Publishing: 11] [Article Influence: 7.3] [Reference Citation Analysis]
127 Coward JI, Middleton K, Murphy F. New perspectives on targeted therapy in ovarian cancer. Int J Womens Health 2015;7:189-203. [PMID: 25678824 DOI: 10.2147/IJWH.S52379] [Cited by in Crossref: 66] [Cited by in F6Publishing: 47] [Article Influence: 11.0] [Reference Citation Analysis]
128 Tam AS, Stirling PC. Splicing, genome stability and disease: splice like your genome depends on it! Curr Genet 2019;65:905-12. [PMID: 30953124 DOI: 10.1007/s00294-019-00964-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
129 Francis JC, Melchor L, Campbell J, Kendrick H, Wei W, Armisen-Garrido J, Assiotis I, Chen L, Kozarewa I, Fenwick K, Swain A, Smalley MJ, Lord CJ, Ashworth A. Whole-exome DNA sequence analysis of Brca2- and Trp53-deficient mouse mammary gland tumours. J Pathol 2015;236:186-200. [PMID: 25692405 DOI: 10.1002/path.4517] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
130 Jiang X, Li X, Li W, Bai H, Zhang Z. PARP inhibitors in ovarian cancer: Sensitivity prediction and resistance mechanisms. J Cell Mol Med 2019;23:2303-13. [PMID: 30672100 DOI: 10.1111/jcmm.14133] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 20.0] [Reference Citation Analysis]
131 Adjiri A. Tracing the path of cancer initiation: the AA protein-based model for cancer genesis. BMC Cancer 2018;18:831. [PMID: 30119662 DOI: 10.1186/s12885-018-4739-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
132 Lima ZS, Ghadamzadeh M, Arashloo FT, Amjad G, Ebadi MR, Younesi L. Recent advances of therapeutic targets based on the molecular signature in breast cancer: genetic mutations and implications for current treatment paradigms. J Hematol Oncol 2019;12:38. [PMID: 30975222 DOI: 10.1186/s13045-019-0725-6] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 13.5] [Reference Citation Analysis]
133 Azim HA, Ghosn M, Oualla K, Kassem L. Personalized treatment in metastatic triple-negative breast cancer: The outlook in 2020. Breast J 2020;26:69-80. [PMID: 31872557 DOI: 10.1111/tbj.13713] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
134 Li A, Yi M, Qin S, Chu Q, Luo S, Wu K. Prospects for combining immune checkpoint blockade with PARP inhibition. J Hematol Oncol 2019;12:98. [PMID: 31521196 DOI: 10.1186/s13045-019-0784-8] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 21.5] [Reference Citation Analysis]
135 Davalos V, Martinez-cardus A, Esteller M. The Epigenomic Revolution in Breast Cancer. The American Journal of Pathology 2017;187:2163-74. [DOI: 10.1016/j.ajpath.2017.07.002] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
136 Scott CL, Swisher EM, Kaufmann SH. Poly (ADP-ribose) polymerase inhibitors: recent advances and future development. J Clin Oncol 2015;33:1397-406. [PMID: 25779564 DOI: 10.1200/JCO.2014.58.8848] [Cited by in Crossref: 223] [Cited by in F6Publishing: 132] [Article Influence: 37.2] [Reference Citation Analysis]
137 Lo CSY, van Toorn M, Gaggioli V, Paes Dias M, Zhu Y, Manolika EM, Zhao W, van der Does M, Mukherjee C, G S C Souto Gonçalves J, van Royen ME, French PJ, Demmers J, Smal I, Lans H, Wheeler D, Jonkers J, Chaudhuri AR, Marteijn JA, Taneja N. SMARCAD1-mediated active replication fork stability maintains genome integrity. Sci Adv 2021;7:eabe7804. [PMID: 33952518 DOI: 10.1126/sciadv.abe7804] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
138 Livraghi L, Garber JE. PARP inhibitors in the management of breast cancer: current data and future prospects. BMC Med 2015;13:188. [PMID: 26268938 DOI: 10.1186/s12916-015-0425-1] [Cited by in Crossref: 160] [Cited by in F6Publishing: 146] [Article Influence: 26.7] [Reference Citation Analysis]
139 Schoonen PM, Talens F, Stok C, Gogola E, Heijink AM, Bouwman P, Foijer F, Tarsounas M, Blatter S, Jonkers J, Rottenberg S, van Vugt MATM. Progression through mitosis promotes PARP inhibitor-induced cytotoxicity in homologous recombination-deficient cancer cells. Nat Commun. 2017;8:15981. [PMID: 28714471 DOI: 10.1038/ncomms15981] [Cited by in Crossref: 54] [Cited by in F6Publishing: 52] [Article Influence: 13.5] [Reference Citation Analysis]
140 Meehan RS, Chen AP. New treatment option for ovarian cancer: PARP inhibitors. Gynecol Oncol Res Pract 2016;3:3. [PMID: 27231574 DOI: 10.1186/s40661-016-0024-7] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 8.8] [Reference Citation Analysis]
141 Seibold P, Schmezer P, Behrens S, Michailidou K, Bolla MK, Wang Q, Flesch-Janys D, Nevanlinna H, Fagerholm R, Aittomäki K, Blomqvist C, Margolin S, Mannermaa A, Kataja V, Kosma VM, Hartikainen JM, Lambrechts D, Wildiers H, Kristensen V, Alnæs GG, Nord S, Borresen-Dale AL, Hooning MJ, Hollestelle A, Jager A, Seynaeve C, Li J, Liu J, Humphreys K, Dunning AM, Rhenius V, Shah M, Kabisch M, Torres D, Ulmer HU, Hamann U, Schildkraut JM, Purrington KS, Couch FJ, Hall P, Pharoah P, Easton DF, Schmidt MK, Chang-Claude J, Popanda O. A polymorphism in the base excision repair gene PARP2 is associated with differential prognosis by chemotherapy among postmenopausal breast cancer patients. BMC Cancer 2015;15:978. [PMID: 26674097 DOI: 10.1186/s12885-015-1957-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
142 Mutter RW, Riaz N, Ng CK, Delsite R, Piscuoglio S, Edelweiss M, Martelotto LG, Sakr RA, King TA, Giri DD, Drobnjak M, Brogi E, Bindra R, Bernheim G, Lim RS, Blecua P, Desrichard A, Higginson D, Towers R, Jiang R, Lee W, Weigelt B, Reis-Filho JS, Powell SN. Bi-allelic alterations in DNA repair genes underpin homologous recombination DNA repair defects in breast cancer. J Pathol 2017;242:165-77. [PMID: 28299801 DOI: 10.1002/path.4890] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 7.0] [Reference Citation Analysis]
143 Wang Y, Bernhardy AJ, Nacson J, Krais JJ, Tan YF, Nicolas E, Radke MR, Handorf E, Llop-Guevara A, Balmaña J, Swisher EM, Serra V, Peri S, Johnson N. BRCA1 intronic Alu elements drive gene rearrangements and PARP inhibitor resistance. Nat Commun 2019;10:5661. [PMID: 31827092 DOI: 10.1038/s41467-019-13530-6] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 11.0] [Reference Citation Analysis]
144 Yan S, Fang J, Chen Y, Xie Y, Zhang S, Zhu X, Fang F. Comprehensive analysis of prognostic gene signatures based on immune infiltration of ovarian cancer. BMC Cancer 2020;20:1205. [PMID: 33287740 DOI: 10.1186/s12885-020-07695-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
145 Adjiri A. Identifying and Targeting the Cause of Cancer is Needed to Cure Cancer. Oncol Ther 2016;4:17-33. [PMID: 28261638 DOI: 10.1007/s40487-015-0015-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
146 Ruiz de Garibay G, Mateo F, Stradella A, Valdés-Mas R, Palomero L, Serra-Musach J, Puente DA, Díaz-Navarro A, Vargas-Parra G, Tornero E, Morilla I, Farré L, Martinez-Iniesta M, Herranz C, McCormack E, Vidal A, Petit A, Soler T, Lázaro C, Puente XS, Villanueva A, Pujana MA. Tumor xenograft modeling identifies an association between TCF4 loss and breast cancer chemoresistance. Dis Model Mech 2018;11:dmm032292. [PMID: 29666142 DOI: 10.1242/dmm.032292] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
147 Trusler O, Goodwin J, Laslett AL. BRCA1 and BRCA2 associated breast cancer and the roles of current modelling systems in drug discovery. Biochim Biophys Acta Rev Cancer 2021;1875:188459. [PMID: 33129865 DOI: 10.1016/j.bbcan.2020.188459] [Reference Citation Analysis]
148 Yi H, Liu L, Sheng N, Li P, Pan H, Cai L, Ma Y. Synergistic Therapy of Doxorubicin and miR-129-5p with Self-Cross-Linked Bioreducible Polypeptide Nanoparticles Reverses Multidrug Resistance in Cancer Cells. Biomacromolecules 2016;17:1737-47. [DOI: 10.1021/acs.biomac.6b00141] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 5.2] [Reference Citation Analysis]
149 Kummar S, Oza AM, Fleming GF, Sullivan DM, Gandara DR, Naughton MJ, Villalona-Calero MA, Morgan RJ Jr, Szabo PM, Youn A, Chen AP, Ji J, Allen DE, Lih CJ, Mehaffey MG, Walsh WD, McGregor PM 3rd, Steinberg SM, Williams PM, Kinders RJ, Conley BA, Simon RM, Doroshow JH. Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer. Clin Cancer Res 2015;21:1574-82. [PMID: 25589624 DOI: 10.1158/1078-0432.CCR-14-2565] [Cited by in Crossref: 80] [Cited by in F6Publishing: 44] [Article Influence: 13.3] [Reference Citation Analysis]
150 Stellato M, Guadalupi V, Sepe P, Mennitto A, Claps M, Zattarin E, Verzoni E, Valdagni R, De Braud FG, Santini D, Tonini G, Procopio G. The emerging role of PARP inhibitors in prostate cancer. Expert Rev Anticancer Ther 2020;20:715-26. [PMID: 32758032 DOI: 10.1080/14737140.2020.1797497] [Reference Citation Analysis]
151 Lupo B, Trusolino L. Inhibition of poly(ADP-ribosyl)ation in cancer: old and new paradigms revisited. Biochim Biophys Acta 2014;1846:201-15. [PMID: 25026313 DOI: 10.1016/j.bbcan.2014.07.004] [Cited by in Crossref: 34] [Cited by in F6Publishing: 58] [Article Influence: 4.9] [Reference Citation Analysis]
152 Liu SM, Chen W, Wang J. Distinguishing between cancer cell differentiation and resistance induced by all-trans retinoic acid using transcriptional profiles and functional pathway analysis. Sci Rep 2014;4:5577. [PMID: 24993014 DOI: 10.1038/srep05577] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
153 Nichol D, Jeavons P, Fletcher AG, Bonomo RA, Maini PK, Paul JL, Gatenby RA, Anderson AR, Scott JG. Steering Evolution with Sequential Therapy to Prevent the Emergence of Bacterial Antibiotic Resistance. PLoS Comput Biol 2015;11:e1004493. [PMID: 26360300 DOI: 10.1371/journal.pcbi.1004493] [Cited by in Crossref: 99] [Cited by in F6Publishing: 61] [Article Influence: 16.5] [Reference Citation Analysis]
154 Palazzo L, Ahel I. PARPs in genome stability and signal transduction: implications for cancer therapy. Biochem Soc Trans 2018;46:1681-95. [PMID: 30420415 DOI: 10.1042/BST20180418] [Cited by in Crossref: 31] [Cited by in F6Publishing: 18] [Article Influence: 10.3] [Reference Citation Analysis]
155 Krais JJ, Johnson N. BRCA1 Mutations in Cancer: Coordinating Deficiencies in Homologous Recombination with Tumorigenesis. Cancer Res 2020;80:4601-9. [PMID: 32747362 DOI: 10.1158/0008-5472.CAN-20-1830] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
156 Seol JH, Shim EY, Lee SE. Microhomology-mediated end joining: Good, bad and ugly. Mutat Res 2018;809:81-7. [PMID: 28754468 DOI: 10.1016/j.mrfmmm.2017.07.002] [Cited by in Crossref: 92] [Cited by in F6Publishing: 81] [Article Influence: 23.0] [Reference Citation Analysis]
157 Gu Y, Bouwman P, Greco D, Saarela J, Yadav B, Jonkers J, Kuznetsov SG. Suppression of BRCA1 sensitizes cells to proteasome inhibitors. Cell Death Dis 2014;5:e1580. [PMID: 25522274 DOI: 10.1038/cddis.2014.537] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
158 Ashworth A, Lord CJ. Synthetic lethal therapies for cancer: what's next after PARP inhibitors? Nat Rev Clin Oncol 2018;15:564-76. [PMID: 29955114 DOI: 10.1038/s41571-018-0055-6] [Cited by in Crossref: 155] [Cited by in F6Publishing: 133] [Article Influence: 77.5] [Reference Citation Analysis]
159 Kim H, George E, Ragland R, Rafail S, Zhang R, Krepler C, Morgan M, Herlyn M, Brown E, Simpkins F. Targeting the ATR/CHK1 Axis with PARP Inhibition Results in Tumor Regression in BRCA-Mutant Ovarian Cancer Models. Clin Cancer Res 2017;23:3097-108. [PMID: 27993965 DOI: 10.1158/1078-0432.CCR-16-2273] [Cited by in Crossref: 118] [Cited by in F6Publishing: 78] [Article Influence: 23.6] [Reference Citation Analysis]
160 Cimmino F, Formicola D, Capasso M. Dualistic Role of BARD1 in Cancer. Genes (Basel) 2017;8:E375. [PMID: 29292755 DOI: 10.3390/genes8120375] [Cited by in Crossref: 30] [Cited by in F6Publishing: 21] [Article Influence: 7.5] [Reference Citation Analysis]
161 Xie Y, Jiang Y, Yang XB, Wang AQ, Zheng YC, Wan XS, Sang XT, Wang K, Zhang DD, Xu JJ, Li FG, Zhao HT. Response of BRCA1-mutated gallbladder cancer to olaparib: A case report. World J Gastroenterol 2016; 22(46): 10254-10259 [PMID: 28028375 DOI: 10.3748/wjg.v22.i46.10254] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
162 Hassan S, Esch A, Liby T, Gray JW, Heiser LM. Pathway-Enriched Gene Signature Associated with 53BP1 Response to PARP Inhibition in Triple-Negative Breast Cancer. Mol Cancer Ther 2017;16:2892-901. [PMID: 28958991 DOI: 10.1158/1535-7163.MCT-17-0170] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
163 Guney Eskiler G, Cecener G, Egeli U, Tunca B. Synthetically Lethal BMN 673 (Talazoparib) Loaded Solid Lipid Nanoparticles for BRCA1 Mutant Triple Negative Breast Cancer. Pharm Res 2018;35. [DOI: 10.1007/s11095-018-2502-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
164 Mackay DR, Howa AC, Werner TL, Ullman KS. Nup153 and Nup50 promote recruitment of 53BP1 to DNA repair foci by antagonizing BRCA1-dependent events. Journal of Cell Science. [DOI: 10.1242/jcs.203513] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.8] [Reference Citation Analysis]
165 Quigley D, Alumkal JJ, Wyatt AW, Kothari V, Foye A, Lloyd P, Aggarwal R, Kim W, Lu E, Schwartzman J, Beja K, Annala M, Das R, Diolaiti M, Pritchard C, Thomas G, Tomlins S, Knudsen K, Lord CJ, Ryan C, Youngren J, Beer TM, Ashworth A, Small EJ, Feng FY. Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP Inhibitors. Cancer Discov 2017;7:999-1005. [PMID: 28450426 DOI: 10.1158/2159-8290.CD-17-0146] [Cited by in Crossref: 133] [Cited by in F6Publishing: 71] [Article Influence: 33.3] [Reference Citation Analysis]
166 Kolinjivadi AM, Sannino V, de Antoni A, Técher H, Baldi G, Costanzo V. Moonlighting at replication forks - a new life for homologous recombination proteins BRCA1, BRCA2 and RAD51. FEBS Lett 2017;591:1083-100. [PMID: 28079255 DOI: 10.1002/1873-3468.12556] [Cited by in Crossref: 87] [Cited by in F6Publishing: 82] [Article Influence: 21.8] [Reference Citation Analysis]
167 Sokolenko AP, Bizin IV, Preobrazhenskaya EV, Gorodnova TV, Ivantsov AO, Iyevleva AG, Savonevich EL, Kotiv KB, Kuligina ES, Imyanitov EN. Molecular profiles of BRCA1-associated ovarian cancer treated by platinum-based therapy: Analysis of primary, residual and relapsed tumors. Int J Cancer. 2020;146:1879-1888. [PMID: 31693165 DOI: 10.1002/ijc.32776] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
168 Wang L, Wang Q, Xu Y, Cui M, Han L. Advances in the Treatment of Ovarian Cancer Using PARP Inhibitors and the Underlying Mechanism of Resistance. Curr Drug Targets 2020;21:167-78. [PMID: 31553293 DOI: 10.2174/1389450120666190925123507] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
169 Pires E, Sung P, Wiese C. Role of RAD51AP1 in homologous recombination DNA repair and carcinogenesis. DNA Repair (Amst) 2017;59:76-81. [PMID: 28963981 DOI: 10.1016/j.dnarep.2017.09.008] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
170 Vyse S, Howitt A, Huang PH. Exploiting Synthetic Lethality and Network Biology to Overcome EGFR Inhibitor Resistance in Lung Cancer. J Mol Biol 2017;429:1767-86. [PMID: 28478283 DOI: 10.1016/j.jmb.2017.04.018] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
171 Reimers MS, Engels CC, Kuppen PJ, van de Velde CJ, Liefers GJ. How does genome sequencing impact surgery? Nat Rev Clin Oncol 2014;11:610-8. [PMID: 24958181 DOI: 10.1038/nrclinonc.2014.101] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
172 Toma M, Sullivan-Reed K, Śliwiński T, Skorski T. RAD52 as a Potential Target for Synthetic Lethality-Based Anticancer Therapies. Cancers (Basel) 2019;11:E1561. [PMID: 31615159 DOI: 10.3390/cancers11101561] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 8.5] [Reference Citation Analysis]
173 Carmichael J, Maza MLDF, Rescigno P, Chandran K, de Bono J. Targeting defective DNA repair in prostate cancer. Curr Opin Oncol 2020;32:503-9. [PMID: 32675592 DOI: 10.1097/CCO.0000000000000654] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
174 Wang Y, Krais JJ, Bernhardy AJ, Nicolas E, Cai KQ, Harrell MI, Kim HH, George E, Swisher EM, Simpkins F, Johnson N. RING domain-deficient BRCA1 promotes PARP inhibitor and platinum resistance. J Clin Invest 2016;126:3145-57. [PMID: 27454289 DOI: 10.1172/JCI87033] [Cited by in Crossref: 48] [Cited by in F6Publishing: 32] [Article Influence: 9.6] [Reference Citation Analysis]
175 Xie H, Wang W, Xia B, Jin W, Lou G. Therapeutic applications of PARP inhibitors in ovarian cancer. Biomed Pharmacother 2020;127:110204. [PMID: 32422564 DOI: 10.1016/j.biopha.2020.110204] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
176 Barroso-Sousa R, Shapiro GI, Tolaney SM. Personalized chemotherapy in triple-negative breast cancer: are we ready for prime time? Stem Cell Investig 2019;6:4. [PMID: 30976601 DOI: 10.21037/sci.2019.02.01] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
177 Anantha RW, Simhadri S, Foo TK, Miao S, Liu J, Shen Z, Ganesan S, Xia B. Functional and mutational landscapes of BRCA1 for homology-directed repair and therapy resistance. Elife 2017;6:e21350. [PMID: 28398198 DOI: 10.7554/eLife.21350] [Cited by in Crossref: 45] [Cited by in F6Publishing: 33] [Article Influence: 11.3] [Reference Citation Analysis]
178 Alkema NG, Wisman GB, van der Zee AG, van Vugt MA, de Jong S. Studying platinum sensitivity and resistance in high-grade serous ovarian cancer: Different models for different questions. Drug Resist Updat 2016;24:55-69. [PMID: 26830315 DOI: 10.1016/j.drup.2015.11.005] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 5.8] [Reference Citation Analysis]
179 Misra S, Zhang X, Wani NA, Sizemore S, Ray A. Both BRCA1-wild type and -mutant triple-negative breast cancers show sensitivity to the NAE inhibitor MLN4924 which is enhanced upon MLN4924 and cisplatin combination treatment. Oncotarget 2020;11:784-800. [PMID: 32166000 DOI: 10.18632/oncotarget.27485] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
180 Gralewska P, Gajek A, Marczak A, Rogalska A. Participation of the ATR/CHK1 pathway in replicative stress targeted therapy of high-grade ovarian cancer. J Hematol Oncol 2020;13:39. [PMID: 32316968 DOI: 10.1186/s13045-020-00874-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 14.0] [Reference Citation Analysis]
181 Zhou J, Gelot C, Pantelidou C, Li A, Yücel H, Davis RE, Farkkila A, Kochupurakkal B, Syed A, Shapiro GI, Tainer JA, Blagg BSJ, Ceccaldi R, D'Andrea AD. A first-in-class Polymerase Theta Inhibitor selectively targets Homologous-Recombination-Deficient Tumors. Nat Cancer 2021;2:598-610. [PMID: 34179826 DOI: 10.1038/s43018-021-00203-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
182 Paradiso AV, Digennaro M, Patruno M, De Summa S, Tommasi S, Berindan-Neagoe I. BRCA germline mutation test for all woman with ovarian cancer? BMC Cancer 2019;19:641. [PMID: 31253107 DOI: 10.1186/s12885-019-5829-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
183 Pettitt SJ, Krastev DB, Brandsma I, Dréan A, Song F, Aleksandrov R, Harrell MI, Menon M, Brough R, Campbell J, Frankum J, Ranes M, Pemberton HN, Rafiq R, Fenwick K, Swain A, Guettler S, Lee JM, Swisher EM, Stoynov S, Yusa K, Ashworth A, Lord CJ. Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance. Nat Commun 2018;9:1849. [PMID: 29748565 DOI: 10.1038/s41467-018-03917-2] [Cited by in Crossref: 139] [Cited by in F6Publishing: 127] [Article Influence: 46.3] [Reference Citation Analysis]
184 Michelena J, Lezaja A, Teloni F, Schmid T, Imhof R, Altmeyer M. Analysis of PARP inhibitor toxicity by multidimensional fluorescence microscopy reveals mechanisms of sensitivity and resistance. Nat Commun 2018;9:2678. [PMID: 29992957 DOI: 10.1038/s41467-018-05031-9] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 14.0] [Reference Citation Analysis]
185 Dréan A, Williamson CT, Brough R, Brandsma I, Menon M, Konde A, Garcia-Murillas I, Pemberton HN, Frankum J, Rafiq R, Badham N, Campbell J, Gulati A, Turner NC, Pettitt SJ, Ashworth A, Lord CJ. Modeling Therapy Resistance in BRCA1/2-Mutant Cancers. Mol Cancer Ther 2017;16:2022-34. [PMID: 28619759 DOI: 10.1158/1535-7163.MCT-17-0098] [Cited by in Crossref: 39] [Cited by in F6Publishing: 21] [Article Influence: 9.8] [Reference Citation Analysis]
186 Ordulu Z, Watkins J, Ritterhouse LL. Molecular Pathology of Ovarian Epithelial Neoplasms: Predictive, Prognostic, and Emerging Biomarkers. Surg Pathol Clin 2021;14:415-28. [PMID: 34373093 DOI: 10.1016/j.path.2021.05.006] [Reference Citation Analysis]
187 García IA, Garro C, Fernandez E, Soria G. Therapeutic opportunities for PLK1 inhibitors: Spotlight on BRCA1-deficiency and triple negative breast cancers. Mutat Res 2020;821:111693. [PMID: 32172132 DOI: 10.1016/j.mrfmmm.2020.111693] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
188 Yang J, Li B, He QY. Significance of prohibitin domain family in tumorigenesis and its implication in cancer diagnosis and treatment. Cell Death Dis 2018;9:580. [PMID: 29784973 DOI: 10.1038/s41419-018-0661-3] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 9.7] [Reference Citation Analysis]
189 Kunze FA, Hottiger MO. Regulating Immunity via ADP-Ribosylation: Therapeutic Implications and Beyond. Trends Immunol 2019;40:159-73. [PMID: 30658897 DOI: 10.1016/j.it.2018.12.006] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 14.0] [Reference Citation Analysis]
190 Zhang J, Dai Q, Park D, Deng X. Targeting DNA Replication Stress for Cancer Therapy. Genes (Basel) 2016;7:E51. [PMID: 27548226 DOI: 10.3390/genes7080051] [Cited by in Crossref: 47] [Cited by in F6Publishing: 38] [Article Influence: 9.4] [Reference Citation Analysis]
191 Kim SM, Yang Y, Oh SJ, Hong Y, Seo M, Jang M. Cancer-derived exosomes as a delivery platform of CRISPR/Cas9 confer cancer cell tropism-dependent targeting. J Control Release 2017;266:8-16. [PMID: 28916446 DOI: 10.1016/j.jconrel.2017.09.013] [Cited by in Crossref: 138] [Cited by in F6Publishing: 133] [Article Influence: 34.5] [Reference Citation Analysis]
192 Colomba E, Pautier P, Pommeret F, Leary A. Rucaparib in the landscape of PARP inhibition in ovarian cancer. Expert Rev Anticancer Ther 2019;19:437-46. [PMID: 30977683 DOI: 10.1080/14737140.2019.1607302] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
193 To C, Kim EH, Royce DB, Williams CR, Collins RM, Risingsong R, Sporn MB, Liby KT. The PARP inhibitors, veliparib and olaparib, are effective chemopreventive agents for delaying mammary tumor development in BRCA1-deficient mice. Cancer Prev Res (Phila) 2014;7:698-707. [PMID: 24817481 DOI: 10.1158/1940-6207.CAPR-14-0047] [Cited by in Crossref: 46] [Cited by in F6Publishing: 25] [Article Influence: 6.6] [Reference Citation Analysis]
194 Teloni F, Altmeyer M. Readers of poly(ADP-ribose): designed to be fit for purpose. Nucleic Acids Res 2016;44:993-1006. [PMID: 26673700 DOI: 10.1093/nar/gkv1383] [Cited by in Crossref: 118] [Cited by in F6Publishing: 106] [Article Influence: 19.7] [Reference Citation Analysis]
195 Wang J, He G, Li H, Ge Y, Wang S, Xu Y, Zhu Q. Discovery of novel PARP/PI3K dual inhibitors with high efficiency against BRCA-proficient triple negative breast cancer. Eur J Med Chem 2021;213:113054. [PMID: 33309164 DOI: 10.1016/j.ejmech.2020.113054] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
196 Kim H, Xu H, George E, Hallberg D, Kumar S, Jagannathan V, Medvedev S, Kinose Y, Devins K, Verma P, Ly K, Wang Y, Greenberg RA, Schwartz L, Johnson N, Scharpf RB, Mills GB, Zhang R, Velculescu VE, Brown EJ, Simpkins F. Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models. Nat Commun 2020;11:3726. [PMID: 32709856 DOI: 10.1038/s41467-020-17127-2] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 23.0] [Reference Citation Analysis]
197 Duma N, Gast KC, Choong GM, Leon-Ferre RA, O'Sullivan CC. Where Do We Stand on the Integration of PARP Inhibitors for the Treatment of Breast Cancer? Curr Oncol Rep 2018;20:63. [PMID: 29884921 DOI: 10.1007/s11912-018-0709-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
198 Romeo M, Pardo JC, Martínez-Cardús A, Martínez-Balibrea E, Quiroga V, Martínez-Román S, Solé F, Margelí M, Mesía R. Translational Research Opportunities Regarding Homologous Recombination in Ovarian Cancer. Int J Mol Sci 2018;19:E3249. [PMID: 30347758 DOI: 10.3390/ijms19103249] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
199 Ma S, Pradeep S, Villar-Prados A, Wen Y, Bayraktar E, Mangala LS, Kim MS, Wu SY, Hu W, Rodriguez-Aguayo C, Leuschner C, Liang X, Ram PT, Schlacher K, Coleman RL, Sood AK. GnRH-R-Targeted Lytic Peptide Sensitizes BRCA Wild-type Ovarian Cancer to PARP Inhibition. Mol Cancer Ther 2019;18:969-79. [PMID: 30926640 DOI: 10.1158/1535-7163.MCT-18-0770] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 3.5] [Reference Citation Analysis]
200 Morgan RD, Clamp AR, Evans DGR, Edmondson RJ, Jayson GC. PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer. Cancer Chemother Pharmacol 2018;81:647-58. [PMID: 29464354 DOI: 10.1007/s00280-018-3532-9] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 13.3] [Reference Citation Analysis]
201 Fang P, De Souza C, Minn K, Chien J. Genome-scale CRISPR knockout screen identifies TIGAR as a modifier of PARP inhibitor sensitivity. Commun Biol 2019;2:335. [PMID: 31508509 DOI: 10.1038/s42003-019-0580-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
202 Takada M, Nagai S, Haruta M, Sugino RP, Tozuka K, Takei H, Ohkubo F, Inoue K, Kurosumi M, Miyazaki M, Sato-Otsubo A, Sato Y, Ogawa S, Kaneko Y. BRCA1 alterations with additional defects in DNA damage response genes may confer chemoresistance to BRCA-like breast cancers treated with neoadjuvant chemotherapy. Genes Chromosomes Cancer 2017;56:405-20. [PMID: 28124401 DOI: 10.1002/gcc.22445] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
203 Westin SN, Sood AK, Coleman RL. Targeted Therapy and Molecular Genetics. Clinical Gynecologic Oncology. Elsevier; 2018. pp. 470-492.e10. [DOI: 10.1016/b978-0-323-40067-1.00018-8] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
204 Xu J, Sun T, Guo X, Wang Y, Jing M. Estrogen receptor-α promoter methylation is a biomarker for outcome prediction of cisplatin resistance in triple-negative breast cancer. Oncol Lett 2018;15:2855-62. [PMID: 29456719 DOI: 10.3892/ol.2017.7637] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
205 Sengodan SK, K H S, Nadhan R, Srinivas P. Regulation of epithelial to mesenchymal transition by BRCA1 in breast cancer. Crit Rev Oncol Hematol 2018;123:74-82. [PMID: 29482782 DOI: 10.1016/j.critrevonc.2018.01.008] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
206 Gillessen S, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow RG, Chi KN, Clarke N, Davis ID, de Bono J, Drake CG, Duran I, Eeles R, Efstathiou E, Evans CP, Fanti S, Feng FY, Fizazi K, Frydenberg M, Gleave M, Halabi S, Heidenreich A, Heinrich D, Higano CTS, Hofman MS, Hussain M, James N, Kanesvaran R, Kantoff P, Khauli RB, Leibowitz R, Logothetis C, Maluf F, Millman R, Morgans AK, Morris MJ, Mottet N, Mrabti H, Murphy DG, Murthy V, Oh WK, Ost P, O'Sullivan JM, Padhani AR, Parker C, Poon DMC, Pritchard CC, Reiter RE, Roach M, Rubin M, Ryan CJ, Saad F, Sade JP, Sartor O, Scher HI, Shore N, Small E, Smith M, Soule H, Sternberg CN, Steuber T, Suzuki H, Sweeney C, Sydes MR, Taplin ME, Tombal B, Türkeri L, van Oort I, Zapatero A, Omlin A. Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. Eur Urol 2020;77:508-47. [PMID: 32001144 DOI: 10.1016/j.eururo.2020.01.012] [Cited by in Crossref: 122] [Cited by in F6Publishing: 103] [Article Influence: 122.0] [Reference Citation Analysis]
207 Lord CJ, Ashworth A. PARP inhibitors: Synthetic lethality in the clinic. Science 2017;355:1152-8. [PMID: 28302823 DOI: 10.1126/science.aam7344] [Cited by in Crossref: 882] [Cited by in F6Publishing: 796] [Article Influence: 220.5] [Reference Citation Analysis]
208 Śniadecki M, Brzeziński M, Darecka K, Klasa-Mazurkiewicz D, Poniewierza P, Krzeszowiec M, Kmieć N, Wydra D. BARD1 and Breast Cancer: The Possibility of Creating Screening Tests and New Preventive and Therapeutic Pathways for Predisposed Women. Genes (Basel) 2020;11:E1251. [PMID: 33114377 DOI: 10.3390/genes11111251] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
209 Esplin ED, Oei L, Snyder MP. Personalized sequencing and the future of medicine: discovery, diagnosis and defeat of disease. Pharmacogenomics 2014;15:1771-90. [PMID: 25493570 DOI: 10.2217/pgs.14.117] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 5.1] [Reference Citation Analysis]
210 Ng CKY, Weigelt B, A'Hern R, Bidard FC, Lemetre C, Swanton C, Shen R, Reis-Filho JS. Predictive performance of microarray gene signatures: impact of tumor heterogeneity and multiple mechanisms of drug resistance. Cancer Res 2014;74:2946-61. [PMID: 24706696 DOI: 10.1158/0008-5472.CAN-13-3375] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
211 Schadt EE, Buchanan S, Brennand KJ, Merchant KM. Evolving toward a human-cell based and multiscale approach to drug discovery for CNS disorders. Front Pharmacol 2014;5:252. [PMID: 25520658 DOI: 10.3389/fphar.2014.00252] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 4.3] [Reference Citation Analysis]
212 Jeggo PA, Pearl LH, Carr AM. DNA repair, genome stability and cancer: a historical perspective. Nat Rev Cancer 2016;16:35-42. [PMID: 26667849 DOI: 10.1038/nrc.2015.4] [Cited by in Crossref: 330] [Cited by in F6Publishing: 292] [Article Influence: 55.0] [Reference Citation Analysis]
213 Dev H, Chiang TW, Lescale C, de Krijger I, Martin AG, Pilger D, Coates J, Sczaniecka-Clift M, Wei W, Ostermaier M, Herzog M, Lam J, Shea A, Demir M, Wu Q, Yang F, Fu B, Lai Z, Balmus G, Belotserkovskaya R, Serra V, O'Connor MJ, Bruna A, Beli P, Pellegrini L, Caldas C, Deriano L, Jacobs JJL, Galanty Y, Jackson SP. Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells. Nat Cell Biol 2018;20:954-65. [PMID: 30022119 DOI: 10.1038/s41556-018-0140-1] [Cited by in Crossref: 139] [Cited by in F6Publishing: 129] [Article Influence: 46.3] [Reference Citation Analysis]
214 Feng L, Li N, Li Y, Wang J, Gao M, Wang W, Chen J. Cell cycle-dependent inhibition of 53BP1 signaling by BRCA1. Cell Discov 2015;1:15019. [PMID: 27462418 DOI: 10.1038/celldisc.2015.19] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 7.2] [Reference Citation Analysis]
215 Liu X, Jiang Y, Nowak B, Qiang B, Cheng N, Chen Y, Plunkett W. Targeting BRCA1/2 deficient ovarian cancer with CNDAC-based drug combinations. Cancer Chemother Pharmacol 2018;81:255-67. [PMID: 29189915 DOI: 10.1007/s00280-017-3483-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
216 Decker JT, Hobson EC, Zhang Y, Shin S, Thomas AL, Jeruss JS, Arnold KB, Shea LD. Systems analysis of dynamic transcription factor activity identifies targets for treatment in Olaparib resistant cancer cells. Biotechnol Bioeng 2017;114:2085-95. [PMID: 28322442 DOI: 10.1002/bit.26293] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
217 Gadducci A, Guerrieri ME. PARP inhibitors alone and in combination with other biological agents in homologous recombination deficient epithelial ovarian cancer: From the basic research to the clinic. Crit Rev Oncol Hematol. 2017;114:153-165. [PMID: 28477743 DOI: 10.1016/j.critrevonc.2017.04.006] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
218 Yalon M, Tuval-Kochen L, Castel D, Moshe I, Mazal I, Cohen O, Avivi C, Rosenblatt K, Aviel-Ronen S, Schiby G, Yahalom J, Amariglio N, Pfeffer R, Lawrence Y, Toren A, Rechavi G, Paglin S. Overcoming Resistance of Cancer Cells to PARP-1 Inhibitors with Three Different Drug Combinations. PLoS One 2016;11:e0155711. [PMID: 27196668 DOI: 10.1371/journal.pone.0155711] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
219 Nickoloff JA, Jones D, Lee SH, Williamson EA, Hromas R. Drugging the Cancers Addicted to DNA Repair. J Natl Cancer Inst 2017;109. [PMID: 28521333 DOI: 10.1093/jnci/djx059] [Cited by in Crossref: 83] [Cited by in F6Publishing: 72] [Article Influence: 20.8] [Reference Citation Analysis]
220 Previs RA, Sood AK, Mills GB, Westin SN. The rise of genomic profiling in ovarian cancer. Expert Rev Mol Diagn 2016;16:1337-51. [PMID: 27828713 DOI: 10.1080/14737159.2016.1259069] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
221 Jiang X, Li W, Li X, Bai H, Zhang Z. Current status and future prospects of PARP inhibitor clinical trials in ovarian cancer. Cancer Manag Res 2019;11:4371-90. [PMID: 31191001 DOI: 10.2147/CMAR.S200524] [Cited by in Crossref: 47] [Cited by in F6Publishing: 23] [Article Influence: 23.5] [Reference Citation Analysis]
222 Moiseyenko VM, Chubenko VA, Moiseyenko FV, Zagorskaya LA, Zaytseva YA, Gesha NE, Zykov EN, Ni VI, Preobrazhenskaya EV, Sokolenko AP, Imyanitov EN. "Lazarus Response" to Olaparib in a Virtually Chemonaive Breast Cancer Patient Carrying Gross BRCA2 Gene Deletion. Cureus. 2018;10:e2150. [PMID: 29651367 DOI: 10.7759/cureus.2150] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
223 Foulkes WD. Made-to-measure medicine: BRCA and gynaecological cancer. The Lancet Oncology 2014;15:783-5. [DOI: 10.1016/s1470-2045(14)70246-3] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
224 van de Stolpe A, den Toonder JM. Circulating Tumor Cells: What Is in It for the Patient? A Vision towards the Future. Cancers (Basel) 2014;6:1195-207. [PMID: 24879438 DOI: 10.3390/cancers6021195] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
225 Park S, Lehner B. Cancer type-dependent genetic interactions between cancer driver alterations indicate plasticity of epistasis across cell types. Mol Syst Biol 2015;11:824. [PMID: 26227665 DOI: 10.15252/msb.20156102] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 6.8] [Reference Citation Analysis]
226 Palakeeti B, Ramesh T, Reddy KV, Konakanchi R, Rao PN, Gobi KV. Identification and Characterisation of Rucaparib Degradation Products and Their Comparison with Known Impurities. Chromatographia 2019;82:591-604. [DOI: 10.1007/s10337-018-3669-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
227 Dizdar O, Arslan C, Altundag K. Advances in PARP inhibitors for the treatment of breast cancer. Expert Opin Pharmacother 2015;16:2751-8. [PMID: 26485111 DOI: 10.1517/14656566.2015.1100168] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 5.5] [Reference Citation Analysis]
228 Sullivan-Reed K, Bolton-Gillespie E, Dasgupta Y, Langer S, Siciliano M, Nieborowska-Skorska M, Hanamshet K, Belyaeva EA, Bernhardy AJ, Lee J, Moore M, Zhao H, Valent P, Matlawska-Wasowska K, Müschen M, Bhatia S, Bhatia R, Johnson N, Wasik MA, Mazin AV, Skorski T. Simultaneous Targeting of PARP1 and RAD52 Triggers Dual Synthetic Lethality in BRCA-Deficient Tumor Cells. Cell Rep 2018;23:3127-36. [PMID: 29898385 DOI: 10.1016/j.celrep.2018.05.034] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 17.5] [Reference Citation Analysis]
229 Ávila-Arroyo S, Nuñez GS, García-Fernández LF, Galmarini CM. Synergistic Effect of Trabectedin and Olaparib Combination Regimen in Breast Cancer Cell Lines. J Breast Cancer 2015;18:329-38. [PMID: 26770239 DOI: 10.4048/jbc.2015.18.4.329] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
230 Dréan A, Lord CJ, Ashworth A. PARP inhibitor combination therapy. Crit Rev Oncol Hematol 2016;108:73-85. [PMID: 27931843 DOI: 10.1016/j.critrevonc.2016.10.010] [Cited by in Crossref: 103] [Cited by in F6Publishing: 92] [Article Influence: 20.6] [Reference Citation Analysis]
231 Soni A, Siemann M, Grabos M, Murmann T, Pantelias GE, Iliakis G. Requirement for Parp-1 and DNA ligases 1 or 3 but not of Xrcc1 in chromosomal translocation formation by backup end joining. Nucleic Acids Res 2014;42:6380-92. [PMID: 24748665 DOI: 10.1093/nar/gku298] [Cited by in Crossref: 70] [Cited by in F6Publishing: 60] [Article Influence: 10.0] [Reference Citation Analysis]
232 Sidorova J. A game of substrates: replication fork remodeling and its roles in genome stability and chemo-resistance. Cell Stress 2017;1:115-33. [PMID: 29355244 DOI: 10.15698/cst2017.12.114] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
233 Yamamoto KN, Hirota K, Takeda S, Haeno H. Evolution of pre-existing versus acquired resistance to platinum drugs and PARP inhibitors in BRCA-associated cancers. PLoS One 2014;9:e105724. [PMID: 25158060 DOI: 10.1371/journal.pone.0105724] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
234 Pulliam N, Fang F, Ozes AR, Tang J, Adewuyi A, Keer H, Lyons J, Baylin SB, Matei D, Nakshatri H, Rassool FV, Miller KD, Nephew KP. An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations. Clin Cancer Res 2018;24:3163-75. [PMID: 29615458 DOI: 10.1158/1078-0432.CCR-18-0204] [Cited by in Crossref: 49] [Cited by in F6Publishing: 31] [Article Influence: 16.3] [Reference Citation Analysis]
235 Arnedos M, Vicier C, Loi S, Lefebvre C, Michiels S, Bonnefoi H, Andre F. Precision medicine for metastatic breast cancer—limitations and solutions. Nat Rev Clin Oncol 2015;12:693-704. [DOI: 10.1038/nrclinonc.2015.123] [Cited by in Crossref: 177] [Cited by in F6Publishing: 157] [Article Influence: 29.5] [Reference Citation Analysis]
236 Ward A, Khanna KK, Wiegmans AP. Targeting homologous recombination, new pre-clinical and clinical therapeutic combinations inhibiting RAD51. Cancer Treat Rev 2015;41:35-45. [PMID: 25467108 DOI: 10.1016/j.ctrv.2014.10.006] [Cited by in Crossref: 72] [Cited by in F6Publishing: 68] [Article Influence: 10.3] [Reference Citation Analysis]
237 Konstantinopoulos PA, Ceccaldi R, Shapiro GI, D'Andrea AD. Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer. Cancer Discov. 2015;5:1137-1154. [PMID: 26463832 DOI: 10.1158/2159-8290.cd-15-0714] [Cited by in Crossref: 347] [Cited by in F6Publishing: 197] [Article Influence: 57.8] [Reference Citation Analysis]
238 Adamson AW, Ding YC, Mendez-Dorantes C, Bailis AM, Stark JM, Neuhausen SL. The RAD52 S346X variant reduces risk of developing breast cancer in carriers of pathogenic germline BRCA2 mutations. Mol Oncol 2020;14:1124-33. [PMID: 32175645 DOI: 10.1002/1878-0261.12665] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
239 Zhang Y, Gao X, Yi J, Sang X, Dai Z, Tao Z, Wang M, Shen L, Jia Y, Xie D, Cheng H, Liu Z, Liu P. BTF3 confers oncogenic activity in prostate cancer through transcriptional upregulation of Replication Factor C. Cell Death Dis 2021;12:12. [PMID: 33414468 DOI: 10.1038/s41419-020-03348-2] [Reference Citation Analysis]
240 Macedo GS, Alemar B, Ashton-Prolla P. Reviewing the characteristics of BRCA and PALB2-related cancers in the precision medicine era. Genet Mol Biol 2019;42:215-31. [PMID: 31067289 DOI: 10.1590/1678-4685-GMB-2018-0104] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
241 Nickoloff JA. DNA Repair Dysregulation in Cancer: From Molecular Mechanisms to Synthetic Lethal Opportunities. In: Wondrak GT, editor. Stress Response Pathways in Cancer. Dordrecht: Springer Netherlands; 2015. pp. 7-28. [DOI: 10.1007/978-94-017-9421-3_2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
242 Fradet-Turcotte A, Sitz J, Grapton D, Orthwein A. BRCA2 functions: from DNA repair to replication fork stabilization. Endocr Relat Cancer 2016;23:T1-T17. [PMID: 27530658 DOI: 10.1530/ERC-16-0297] [Cited by in Crossref: 40] [Cited by in F6Publishing: 20] [Article Influence: 8.0] [Reference Citation Analysis]
243 Benada J, Macurek L. Targeting the Checkpoint to Kill Cancer Cells. Biomolecules. 2015;5:1912-1937. [PMID: 26295265 DOI: 10.3390/biom5031912] [Cited by in Crossref: 70] [Cited by in F6Publishing: 64] [Article Influence: 11.7] [Reference Citation Analysis]
244 Hottiger MO. Poly(ADP-ribose) polymerase inhibitor therapeutic effect: are we just scratching the surface? Expert Opin Ther Targets 2015;19:1149-52. [PMID: 26212149 DOI: 10.1517/14728222.2015.1073262] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]